Literature DB >> 14982761

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Laura K Najvar1, Anthony Cacciapuoti, Steve Hernandez, Judith Halpern, Rosie Bocanegra, Maya Gurnani, Frederick Menzel, David Loebenberg, John R Graybill.   

Abstract

Posaconazole and/or amphotericin B was given to mice pretreated with a steroid and then infected by inhalation of Aspergillus flavus conidia. Two laboratories conducted studies using almost identical protocols to evaluate both survival and lung tissue burdens 8 days after infection. The results of the in vivo studies performed at both laboratories were consistent. We found that (i). up to 5 mg of amphotericin B per kg of body weight was poorly effective in treating invasive aspergillosis; (ii). posaconazole at 2 or 10 mg/kg/dose prolonged survival and reduced lung tissue CFU; and (iii). there was generally no antagonistic interaction of the drugs in combination, even when the experiments were designed to maximize the likelihood of antagonism. These studies do not confirm the antagonistic interaction of triazoles and polyenes reported by others.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982761      PMCID: PMC353105          DOI: 10.1128/AAC.48.3.758-764.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.

Authors:  T Yeghen; C C Kibbler; H G Prentice; L A Berger; R K Wallesby; P H McWhinney; F C Lampe; S Gillespie
Journal:  Clin Infect Dis       Date:  2000-10-10       Impact factor: 9.079

2.  Device for inhalation exposure of animals to spores.

Authors:  W R PIGGOTT; C W EMMONS
Journal:  Proc Soc Exp Biol Med       Date:  1960-04

3.  Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

Authors:  A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

4.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Authors:  D P Kontoyiannis; R E Lewis; N Sagar; G May; R A Prince; K V Rolston
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

Authors:  A M Sugar; X P Liu
Journal:  Med Mycol       Date:  2000-06       Impact factor: 4.076

Review 7.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

8.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.

Authors:  A Polak; H J Scholer; M Wall
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

10.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.

Authors:  A Schaffner; P G Frick
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  17 in total

1.  Challenges in designing animal studies to detect antagonism of polyene activity.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis; Dimitrios P Kantoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Authors:  Barbara J Hoeben; David S Burgess; Jason T McConville; Laura K Najvar; Robert L Talbert; Jay I Peters; Nathan P Wiederhold; Bradi L Frei; John R Graybill; Rosie Bocanegra; Kirk A Overhoff; Prapasri Sinswat; Keith P Johnston; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; John R Graybill; Laura K Najvar; Lisa Y Chiang; Thomas Doedt; William R Kirkpatrick; Rosie Bocanegra; Ana C Vallor; Thomas F Patterson; Scott G Filler
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 7.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

8.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Anna M Schimizzi; Monia Maracci; Daniele Giannini; Flavia Carle; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Authors:  A Elefanti; J W Mouton; P E Verweij; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.